This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
14 Aug 2017

Tyme Technologies announces the issuance of two new platform patents

The two patents represent the next generation of SM-88, joining tyrosine and melanin into a potentially more potent combination.

Tyme, a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, announced the US Patent and Trademark Office has issued patents, #9,585,841 (‘841) and #9,724,657 (‘657), that, individually and in combination, substantially expand the scope of intellectual property for Tyme’s pipeline.

“Tyme is focused on using a truly new perspective to solve old problems. For our immediate pipeline, these two patents represent the next generation of SM-88, joining tyrosine and melanin into what we believe will be a more potent combination,” said Steve Hoffman, Tyme’s CEO. “Equally important, both of these patents represent substantial internal and external development opportunities to create novel combinations in the battle against cancer.”

Patent ‘841 describes the process for combining tyrosine derivatives with other compounds, including melanin, as a drug delivery pathway into cancer cells. Tyrosine is the core component of Tyme’s SM-88 therapy and melanin is believed to enhance the oxidative effect of SM-88, which could be further amplified by intracellular delivery. Tyme believes both SM-88’s human clinical trials, as well as tyrosine-based products for diagnostic imaging, have demonstrated that tyrosine is highly selective to cancer cells. Future development projects could combine other drugs with tyrosine to achieve targeted delivery of additional therapeutics into the tumour.

Patent ‘657 describes a novel manufacturing technique to combine compounds under exceptional force. Tyme has demonstrated the use of this technique to combine tyrosine and melanin while maintaining the functionality of their original, separate components. ‘657 is not limited to Tyme’s current product portfolio and could be utilized with a multitude of drug combinations.

Related News